COVID-19 Vaccine-Associated Autoimmune Diseases and Disorders
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Efficacy and Safety".
Deadline for manuscript submissions: 30 April 2024 | Viewed by 219
Special Issue Editor
Special Issue Information
Dear Colleagues,
The interplay between vaccines and autoimmunity is well-known. Patients with autoimmune rheumatic diseases are of great concern regarding COVID-19 infection and vaccination. SLE patients have a higher risk for COVID-19-related complications, including mortality, compared to age- and sex-adjusted controls and patients presenting other autoimmune rheumatic disease conditions. On the other hand, the risk of an increase in patients presenting autoimmune rheumatic diseases following the COVID-19 vaccine has raised some concerns. However, overall, COVID-19 vaccine appears to be safe among SLE patients, with a low rate of severe adverse effects.
In addition, new-onset cases of autoimmune rheumatic diseases among previously healthy patients vaccinated against COVID-19 have recently emerged. New-onset cases of autoimmune rheumatic disorders following COVID-19 vaccination have been reported, mainly as new cases of antineutrophilic cytoplasmic antibody (ANCA) vasculitis, systemic lupus erythematosus, new-onset inflammatory arthritis, Sjogren’s syndrome, autoimmune hepatitis, and neurological conditions.
To improve the understanding of the relationship between vaccines and new diagnoses of autoimmune diseases, this Special Issue of Vaccines focuses on researching this phenomenon. We encourage researchers to contribute original studies, reports, and reviews of the epidemiology, molecular pathways, and clinical and management of new-onset autoimmune conditions related to vaccine uptake.
Dr. Iftach Sagy
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- post-COVID-19
- vaccine
- autoimmune disorders
- systemic lupus erythematosus
- rheumatoid arthritis
- ANCA vasculitis
